Organic Process Research & Development · 2024 · 11 citations · 3 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoverySignal TransductionGlucagon-like Peptide-1 Receptor AgonistsPancreatic HormonesPeptide Drug DiscoveryAlkylation ProcessesAlkylation ReactionsGlp-1 Receptor PharmacologyGlucagon Receptor AgonistsGlucagon-like Peptide 1 Receptor AgonismProduct Development ProcessSmall-molecule Glp-1 Receptor AgonistsWeight Loss Drug
The target compound PF-06878031 is a key structural fragment of a range of oral late-stage glucagon-like peptide-1 receptor agonists (GLP-1-RA) under development in our laboratories for the indications of type-2 diabetes mellitus (T2DM) and weight loss. This article describes the identification of a selective alkylation route and development of a process, capable of delivering multikilo quantities of PF-06878031 . Process development afforded improved safety, increased yield, reduced step count, and lowered PMI. The new process has been scaled up at multiple facilities to generate >1.5MT of high purity PF-06878031 .
3